VistaGen Short Long Term Debt vs Net Working Capital Analysis

VTGN Stock

USD 2.48 0.03 1.20%

VistaGen Therapeutics financial indicator trend analysis is much more than just breaking down VistaGen Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VistaGen Therapeutics is a good investment. Please check the relationship between VistaGen Therapeutics Short Long Term Debt and its Net Working Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.

Short Long Term Debt vs Net Working Capital

Short Long Term Debt vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VistaGen Therapeutics Short Long Term Debt account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between VistaGen Therapeutics' Short Long Term Debt and Net Working Capital is -0.4. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of VistaGen Therapeutics, assuming nothing else is changed. The correlation between historical values of VistaGen Therapeutics' Short Long Term Debt and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of VistaGen Therapeutics are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Short Long Term Debt i.e., VistaGen Therapeutics' Short Long Term Debt and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.4

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Net Working Capital

Most indicators from VistaGen Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VistaGen Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.As of the 12th of December 2024, Issuance Of Capital Stock is likely to grow to about 135.8 M, while Selling General Administrative is likely to drop about 13.4 M.

VistaGen Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Property Plant And Equipment Net	Non Current Assets Total	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Term Debt	Other Current Liab	Other Liab	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Long Term Debt
Total Assets		0.05	0.99	-1.0	0.18	0.03	1.0	1.0	0.89	-0.1	-0.18	0.18	1.0	0.54	-0.09	0.54	0.69	0.24	0.77	-0.14	0.58	0.02	-0.03	0.8	0.85	-0.41
Total Current Liabilities	0.05		-0.03	0.01	0.12	0.56	0.05	0.05	0.06	-0.28	-0.12	0.77	0.05	0.03	0.89	0.03	0.04	0.05	0.05	0.95	0.35	0.33	0.21	0.07	0.07	-0.14
Total Stockholder Equity	0.99	-0.03		-1.0	0.21	-0.03	0.99	0.99	0.89	-0.05	-0.21	0.08	0.99	0.51	-0.19	0.51	0.66	0.17	0.76	-0.22	0.56	-0.06	-0.08	0.79	0.84	-0.43
Net Debt	-1.0	0.01	-1.0		-0.19	0.03	-1.0	-1.0	-0.88	0.07	0.19	-0.12	-1.0	-0.53	0.17	-0.53	-0.66	-0.21	-0.75	0.21	-0.57	0.03	0.05	-0.78	-0.83	0.42
Retained Earnings	0.18	0.12	0.21	-0.19		0.06	0.18	0.18	0.18	0.09	-1.0	-0.22	0.18	0.09	-0.16	0.2	0.21	-0.49	0.21	0.06	0.35	-0.73	-0.18	0.22	0.21	-0.59
Accounts Payable	0.03	0.56	-0.03	0.03	0.06		0.02	0.02	0.3	-0.54	-0.06	0.54	0.02	0.2	0.56	0.33	0.32	0.2	0.34	0.36	0.18	0.39	0.18	0.33	0.28	-0.02
Cash	1.0	0.05	0.99	-1.0	0.18	0.02		1.0	0.88	-0.09	-0.18	0.18	1.0	0.52	-0.09	0.52	0.66	0.23	0.76	-0.14	0.57	0.02	-0.04	0.78	0.84	-0.4
Cash And Short Term Investments	1.0	0.05	0.99	-1.0	0.18	0.02	1.0		0.88	-0.09	-0.18	0.18	1.0	0.52	-0.09	0.52	0.66	0.23	0.76	-0.14	0.57	0.02	-0.04	0.78	0.84	-0.4
Common Stock Total Equity	0.89	0.06	0.89	-0.88	0.18	0.3	0.88	0.88		-0.13	-0.18	0.17	0.88	0.5	-0.09	0.68	0.82	0.21	0.87	-0.19	0.65	0.08	-0.12	0.96	0.97	-0.42
Common Stock Shares Outstanding	-0.1	-0.28	-0.05	0.07	0.09	-0.54	-0.09	-0.09	-0.13		-0.09	-0.46	-0.1	-0.14	-0.26	-0.18	-0.19	-0.4	-0.17	-0.13	-0.04	-0.26	-0.62	-0.14	-0.12	0.27
Other Stockholder Equity	-0.18	-0.12	-0.21	0.19	-1.0	-0.06	-0.18	-0.18	-0.18	-0.09		0.22	-0.18	-0.09	0.16	-0.2	-0.21	0.49	-0.21	-0.06	-0.35	0.73	0.18	-0.22	-0.21	0.59
Total Liab	0.18	0.77	0.08	-0.12	-0.22	0.54	0.18	0.18	0.17	-0.46	0.22		0.18	0.29	0.87	0.33	0.3	0.67	0.26	0.66	0.27	0.73	0.45	0.2	0.17	0.04
Total Current Assets	1.0	0.05	0.99	-1.0	0.18	0.02	1.0	1.0	0.88	-0.1	-0.18	0.18		0.53	-0.09	0.52	0.67	0.23	0.76	-0.14	0.57	0.01	-0.04	0.79	0.84	-0.41
Common Stock	0.54	0.03	0.51	-0.53	0.09	0.2	0.52	0.52	0.5	-0.14	-0.09	0.29	0.53		-0.02	0.65	0.61	0.43	0.64	-0.2	0.38	0.07	0.22	0.42	0.35	-0.25
Short Long Term Debt Total	-0.09	0.89	-0.19	0.17	-0.16	0.56	-0.09	-0.09	-0.09	-0.26	0.16	0.87	-0.09	-0.02		-0.01	-0.02	0.33	-0.03	0.88	0.06	0.61	0.22	-0.05	-0.06	0.22
Property Plant And Equipment Net	0.54	0.03	0.51	-0.53	0.2	0.33	0.52	0.52	0.68	-0.18	-0.2	0.33	0.52	0.65	-0.01		0.96	0.48	0.91	-0.2	0.45	0.15	0.12	0.79	0.71	-0.47
Non Current Assets Total	0.69	0.04	0.66	-0.66	0.21	0.32	0.66	0.66	0.82	-0.19	-0.21	0.3	0.67	0.61	-0.02	0.96		0.44	0.97	-0.2	0.48	0.14	0.06	0.91	0.85	-0.5
Non Current Liabilities Total	0.24	0.05	0.17	-0.21	-0.49	0.2	0.23	0.23	0.21	-0.4	0.49	0.67	0.23	0.43	0.33	0.48	0.44		0.36	-0.06	0.03	0.76	0.45	0.24	0.2	0.23
Property Plant And Equipment Gross	0.77	0.05	0.76	-0.75	0.21	0.34	0.76	0.76	0.87	-0.17	-0.21	0.26	0.76	0.64	-0.03	0.91	0.97	0.36		-0.2	0.49	0.11	0.04	0.91	0.89	-0.5
Short Term Debt	-0.14	0.95	-0.22	0.21	0.06	0.36	-0.14	-0.14	-0.19	-0.13	-0.06	0.66	-0.14	-0.2	0.88	-0.2	-0.2	-0.06	-0.2		0.13	0.28	0.18	-0.17	-0.15	-0.03
Other Current Liab	0.58	0.35	0.56	-0.57	0.35	0.18	0.57	0.57	0.65	-0.04	-0.35	0.27	0.57	0.38	0.06	0.45	0.48	0.03	0.49	0.13		-0.09	-0.13	0.6	0.59	-0.45
Other Liab	0.02	0.33	-0.06	0.03	-0.73	0.39	0.02	0.02	0.08	-0.26	0.73	0.73	0.01	0.07	0.61	0.15	0.14	0.76	0.11	0.28	-0.09		0.34	0.1	0.08	0.5
Current Deferred Revenue	-0.03	0.21	-0.08	0.05	-0.18	0.18	-0.04	-0.04	-0.12	-0.62	0.18	0.45	-0.04	0.22	0.22	0.12	0.06	0.45	0.04	0.18	-0.13	0.34		-0.1	-0.13	-0.28
Non Currrent Assets Other	0.8	0.07	0.79	-0.78	0.22	0.33	0.78	0.78	0.96	-0.14	-0.22	0.2	0.79	0.42	-0.05	0.79	0.91	0.24	0.91	-0.17	0.6	0.1	-0.1		0.99	-0.49
Other Assets	0.85	0.07	0.84	-0.83	0.21	0.28	0.84	0.84	0.97	-0.12	-0.21	0.17	0.84	0.35	-0.06	0.71	0.85	0.2	0.89	-0.15	0.59	0.08	-0.13	0.99		-0.47
Long Term Debt	-0.41	-0.14	-0.43	0.42	-0.59	-0.02	-0.4	-0.4	-0.42	0.27	0.59	0.04	-0.41	-0.25	0.22	-0.47	-0.5	0.23	-0.5	-0.03	-0.45	0.5	-0.28	-0.49	-0.47

Click cells to compare fundamentals

VistaGen Therapeutics Account Relationship Matchups

VistaGen Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	5.8M	108.3M	74.6M	21.1M	123.7M	129.8M
Total Current Liabilities	2.8M	4.2M	5.8M	4.6M	5.1M	3.8M
Total Stockholder Equity	(5.7M)	92.0M	64.7M	12.1M	114.3M	120.0M
Net Debt	2.7M	(99.4M)	(65.1M)	(13.9M)	(117.0M)	(111.2M)
Retained Earnings	(201.9M)	(219.8M)	(267.6M)	(326.9M)	(356.2M)	(374.0M)
Accounts Payable	1.8M	838.3K	2.8M	2.5M	1.5M	1.4M
Cash	1.4M	103.1M	68.1M	16.6M	119.2M	125.1M
Cash And Short Term Investments	1.4M	103.1M	68.1M	16.6M	119.2M	125.1M
Common Stock Total Equity	42.8K	49.3K	180.8K	206.7K	237.7K	249.6K
Common Stock Shares Outstanding	1.5M	2.9M	6.6M	7.0M	19.4M	11.6M
Liabilities And Stockholders Equity	5.8M	108.3M	74.6M	21.1M	123.7M	129.8M
Other Stockholder Equity	196.1M	311.6M	332.3M	338.9M	470.5M	446.9M
Total Liab	11.5M	16.3M	9.9M	9.0M	9.4M	8.3M
Total Current Assets	1.6M	104.1M	71.0M	17.5M	120.7M	126.7M
Common Stock	49.3K	180.8K	206.7K	7.3K	27K	41.8K
Short Long Term Debt Total	4.1M	3.7M	3.0M	2.7M	2.1M	3.1M
Property Plant And Equipment Net	3.8M	3.6M	3.1M	2.8M	2.3M	1.2M
Non Current Assets Total	4.2M	4.2M	3.6M	3.6M	3.0M	3.1M
Non Current Liabilities Total	8.7M	12.1M	4.2M	4.4M	4.2M	4.8M
Property Plant And Equipment Gross	3.8M	3.6M	4.3M	2.8M	3.5M	3.7M
Short Term Debt	373.2K	367.8K	433.3K	591K	1.1M	1.0M
Other Current Liab	561.5K	1.6M	1.3M	1.5M	1.7M	1.1M
Non Currrent Assets Other	402.9K	576.8K	569.1K	814.2K	726K	762.3K
Other Assets	402.9K	576.8K	569.1K	814.2K	936.3K	983.1K
Retained Earnings Total Equity	(181.1M)	(201.9M)	(219.8M)	(267.6M)	(240.8M)	(228.8M)
Other Current Assets	2.7K	968.6K	2.9M	869K	1.5M	1.6M
Deferred Long Term Liab	355.1K	529K	468.2K	713.3K	820.3K	861.3K
Property Plant Equipment	3.8M	3.6M	414.3K	2.8M	3.2M	3.3M
Net Tangible Assets	(5.7M)	92.0M	64.7M	12.1M	13.9M	18.8M
Capital Surpluse	192.1M	200.1M	315.6M	336.1M	386.5M	214.3M
Capital Lease Obligations	4.0M	3.7M	3.0M	2.6M	2.1M	1.9M

Pair Trading with VistaGen Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with VistaGen Stock

0.87	VALN	Valneva SE ADR	Pair Corr
0.84	ERNA	Eterna Therapeutics	Pair Corr

Moving against VistaGen Stock

0.78	BMY	Bristol Myers Squibb	Pair Corr
0.72	ESPR	Esperion Therapeutics	Pair Corr
0.7	DYAI	Dyadic International	Pair Corr
0.5	GILD	Gilead Sciences	Pair Corr
0.37	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.

The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:

How To Invest In VistaGen

Details

Is VistaGen Stock a good investment?

Details

What is VistaGen Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.74)

Revenue Per Share

0.029

Quarterly Revenue Growth

(0.34)

Return On Assets

(0.39)

Return On Equity

(0.62)

The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

VistaGen Short Long Term Debt vs Net Working Capital Analysis

Short Long Term Debt vs Net Working Capital

Short Long Term Debt vs Net Working Capital Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Net Working Capital

VistaGen Therapeutics fundamental ratios Correlations

VistaGen Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

VistaGen Therapeutics fundamental ratios Accounts

Pair Trading with VistaGen Therapeutics

Moving together with VistaGen Stock

Moving against VistaGen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Other Stockholder Equity	- 1.0	Retained Earnings
Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Net Debt	- 1.0	Total Assets